NewAmsterdam Pharma Company NV- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 NewAmsterdam Pharma Company NV 公司

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.

NewAmsterdam Pharma Company NV簡介



公司代碼NAMS

公司名稱NewAmsterdam Pharma Company NV

上市日期Nov 23, 2022

CEODavidson (Michael Harvey)

員工數量68

證券類型Ordinary Share

年結日Nov 23

公司地址Gooimeer 2-35

城市NAARDEN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Netherlands

郵編1411 DC

電話31352062971

網址https://ir.newamsterdampharma.com/

公司代碼NAMS

上市日期Nov 23, 2022

CEODavidson (Michael Harvey)

NewAmsterdam Pharma Company NV公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Mark C. Mckenna

Independent Director

10.36K

+3400.00%

Mr. John W. Smither

Temporary Non-Executive Independent Director

3.40K

+3400.00%

Mr. William H. (Will) Lewis, J.D.

Independent Chairman of the Board

3.40K

+3400.00%

Dr. James N. Topper, M.D., Ph.D.

Independent Director

--

Dr. Michael Harvey Davidson, M.D.

Chief Executive Officer, Executive Director

--

Dr. John Kastelein

Chief Scientific Officer, Non-Executive Director

--

Ms. Juliette Audet

Chief Business Officer

--

Dr. Louis Lange, M.D., Ph.D.

Independent Director

--

Dr. Nicholas Downing, M.D.

Director

--

Ms. Janneke Van Der Kamp

Temporary Non-Executive Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Mark C. Mckenna

Independent Director

10.36K

+3400.00%

Mr. John W. Smither

Temporary Non-Executive Independent Director

3.40K

+3400.00%

Mr. William H. (Will) Lewis, J.D.

Independent Chairman of the Board

3.40K

+3400.00%

Dr. James N. Topper, M.D., Ph.D.

Independent Director

--

Dr. Michael Harvey Davidson, M.D.

Chief Executive Officer, Executive Director

--

Dr. John Kastelein

Chief Scientific Officer, Non-Executive Director

--

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月19日週三

持股股東

股東類型

持股股東

佔比

Frazier Life Sciences Management, L.P.

14.73%

RA Capital Management, LP

8.94%

Capital World Investors

8.66%

Forbion Capital Partners

8.12%

Viking Global Investors LP

5.71%

其他

53.83%

持股股東

佔比

Frazier Life Sciences Management, L.P.

14.73%

RA Capital Management, LP

8.94%

Capital World Investors

8.66%

Forbion Capital Partners

8.12%

Viking Global Investors LP

5.71%

其他

53.83%

股東類型

持股股東

佔比

Investment Advisor

29.24%

Investment Advisor/Hedge Fund

23.40%

Venture Capital

20.18%

Private Equity

14.73%

Hedge Fund

13.05%

Research Firm

2.37%

Family Office

1.70%

Sovereign Wealth Fund

1.00%

Individual Investor

0.56%

機構持股



更新時間: 1月1日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

317

118.25M

104.29%

-6.54M

2025Q3

283

121.74M

107.54%

+4.12M

2025Q2

263

127.89M

114.87%

+4.67M

2025Q1

255

126.71M

112.87%

+7.17M

2024Q4

216

108.34M

98.72%

+13.96M

2024Q3

194

82.73M

88.90%

-12.05M

2024Q2

184

81.92M

90.19%

-12.22M

2024Q1

155

81.92M

90.50%

-4.21M

2023Q4

117

72.34M

86.57%

-9.73M

2023Q3

116

71.44M

85.50%

-13.42M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Frazier Life Sciences Management, L.P.

16.70M

14.73%

--

Nov 01, 2025

RA Capital Management, LP

10.14M

8.94%

--

Sep 30, 2025

Capital World Investors

9.82M

8.66%

+1.43M

+17.11%

Sep 30, 2025

Forbion Capital Partners

9.21M

8.12%

-1.37M

-12.92%

Sep 30, 2025

Viking Global Investors LP

6.48M

5.71%

-503.00K

-7.21%

Sep 30, 2025

Bain Capital Life Sciences Investors, LLC

5.67M

5%

-4.80M

-45.83%

Dec 02, 2025

Fidelity Management & Research Company LLC

5.39M

4.76%

+3.57M

+195.28%

Sep 30, 2025

Deerfield Management Company, L.P.

4.27M

3.76%

-849.26K

-16.60%

Sep 30, 2025

Wellington Management Company, LLP

4.02M

3.55%

+697.13K

+20.98%

Sep 30, 2025

Jennison Associates LLC

4.20M

3.7%

+1.25M

+42.51%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Global X Guru Index ETF

1.82%

ALPS Medical Breakthroughs ETF

1.81%

Virtus LifeSci Biotech Clinical Trials ETF

1.22%

First Trust Small Cap Growth AlphaDEX Fund

1.05%

First Trust NASDAQ Pharmaceuticals ETF

0.83%

Capital Group US Small and Mid Cap ETF

0.68%

ProShares Ultra Nasdaq Biotechnology

0.57%

Invesco Dorsey Wright SmallCap Momentum ETF

0.55%

First Trust Small Cap Core Alphadex Fund

0.43%

Invesco Nasdaq Biotechnology ETF

0.42%

Global X Guru Index ETF

佔比1.82%

ALPS Medical Breakthroughs ETF

佔比1.81%

Virtus LifeSci Biotech Clinical Trials ETF

佔比1.22%

First Trust Small Cap Growth AlphaDEX Fund

佔比1.05%

First Trust NASDAQ Pharmaceuticals ETF

佔比0.83%

Capital Group US Small and Mid Cap ETF

佔比0.68%

ProShares Ultra Nasdaq Biotechnology

佔比0.57%

Invesco Dorsey Wright SmallCap Momentum ETF

佔比0.55%

First Trust Small Cap Core Alphadex Fund

佔比0.43%

Invesco Nasdaq Biotechnology ETF

佔比0.42%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據